ArticleScientific reports2025
The global, regional, and national burden trends of dengue among adults aged 20-49 from 1990 to 2021.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Emergence of dengue at high altitude: characterization of the 2024 outbreak in Cochabamba, Bolivia.Virology journal · 2026Article
- Epidemiological Characteristics of Dengue Disease in Mexico (2014-2025): A Descriptive Analysis of a Hyperendemic Country.Pathogens (Basel, Switzerland) · 2026Review
- Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.Frontiers in immunology · 2026Review
- Article
- Review of selected mosquito-borne diseases: arboviruses (dengue, chikungunya, Zika, West Nile, Japanese encephalitis, yellow fever) and parasitic diseases (malaria, lymphatic Filariasis).Frontiers in public health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The current status and trends in the burden of dengue among adults aged 20-49 years are still unclear. In light of this, based on data from Global Burden of Disease (GBD) 2021, the study explored the global burden of dengue in this age groups, as well as the regional and national burdens, from 1990 to 2021, in aid of more effective strategies for providence and control. We retrieved data from the GBD 2021 with age-standardized incidence rate (ASIR), prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life years rate (ASDR) due to dengue. Estimated annual percentage changes (EAPCs) quantified trends in these rates. The analysis examined temporal changes in disease burden, the relationship between the socio-demographic index (SDI) and disease burden, and the contributions of population growth, increasing age, and epidemiological changes. Projections for 2022 to 2030 were also included. In 2021, the global ASIR, ASPR, ASMR, and ASDR for dengue among adults were recorded at 763.39, 45.54, 0.22, and 19.67 per 100,000 population (person-year), respectively. Notably, these metrics exhibited EAPCs exceeding 2% from 1990 to 2021. The middle SDI region showed the highest ASIR and ASPR for dengue, while the low-middle SDI region showed the highest ASMR and ASDR. Among the 21 GBD regions, Tropical Latin America showed the highest ASIR, ASPR, and ASDR, while Southeast Asia showed the highest ASMR. Overall, a weak negative linear relationship occurred between the SDI and various indicators of dengue burden. Notably, increases in ASIR, ASPR, and ASDR were most pronounced in high-income North America, while the largest decreases were examined in the eastern Sub-Saharan Africa. In addition, ASIR and ASPR were higher in women, whereas ASMR and ASDR were higher in men. Projection analyses showed that by 2030, the ASIR and ASMR for dengue in adults were expected to increase to 872.94 per 100,000 population and 0.24 per 100,000 population, respectively. The global, regional, and national dengue burden in adults aged 20-49 years varied significantly, with steady growth of over 2% annually between 1990 and 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.